screen_shot_2013-03-06_at_10

Glide Pharma appoints chief executive

pharmafile | March 6, 2013 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing Glide Pharma 

Life sciences development and device firm Glide Pharma has announced the appointment of Dr Mark Carnegie-Brown as its chief executive.

Carnegie-Brown brings 25 years’ experience to Glide and was previously the chief executive of Evolutec, a biological drug development business, where he established the company’s clinical and manufacturing programmes.

He was also chief executive of Aenova, a pharmaceutical tablet and capsule manufacturer, where he led the integration of the Swisscaps and Dragenopharm organisations.

Advertisement

Carnegie-Brown started his career in R&D at ICI and subsequently held a number of commercial roles before becoming general manager of Zeneca’s UK and Eire business.

“I am delighted to welcome Mark to Glide Pharma,” said Mark Kirby, Glide Pharma’s chairman. “His research and commercial experience, and in particular his expertise in building successful clinical and manufacturing programmes, will prove invaluable as Glide scales up its capabilities and advances the development of its in-house programmes.

“I would also like to take this opportunity to thank Dr Ian Smith, our previous chief executive, for his contribution to the success of Glide, and I look forward to his continuing support as a member of the company’s Board.”

Carnegie-Brown added: “Glide is in a truly transformational period in its development, and I am delighted to have this opportunity to lead the organisation.”

Related Content

No items found
The Gateway to Local Adoption Series

Latest content